BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 16736414)

  • 1. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron.
    Gotloib L; Silverberg D; Fudin R; Shostak A
    J Nephrol; 2006; 19(2):161-7. PubMed ID: 16736414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
    Stancu S; Bârsan L; Stanciu A; Mircescu G
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S; Maltez C; Lopes AI
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
    Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
    J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
    Usmanov RI; Zueva EB; Silverberg DS; Shaked M
    J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
    Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
    Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia].
    Cançado RD; Brasil SA; Noronha TG; Chiattone CS
    Rev Assoc Med Bras (1992); 2005; 51(6):323-8. PubMed ID: 16444338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
    Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
    Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.
    Cesarano D; Borrelli S; Campilongo G; D'Ambra A; Papadia F; Garofalo C; De Marco A; Marzano F; Ruotolo C; Gesualdo L; Cirillo P; Minutolo R
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.